We're adding 2 stocks to the Bullpen that can benefit from the market rotation

Stocks slipped Monday amid worries about stretched tech valuations and heavy, debt-funded AI and data-center spending; Amazon said it will raise about $15 billion in its first bond sale in three years, tapped to banks including Goldman Sachs, JPMorgan and Morgan Stanley. CNBC’s Investing Club added Kimberly‑Clark and Johnson & Johnson as rotation plays away from tech: Kimberly‑Clark’s contentious acquisition of Kenvue values the target at roughly $49 billion, knocked the stock about 14% and the club highlights $2.4 billion of potential synergies, a sub‑14x 2026 EPS multiple and a 4.8% yield as reasons to buy. Johnson & Johnson, up ~38% YTD, is leaning into oncology (reported $21 billion in 2024 sales, targeting >$50 billion by 2030), announced the purchase of Halda Therapeutics and is spinning off its ~$9 billion orthopedics unit to reallocate capital toward higher‑growth franchises; both names are presented as defensive, cash‑generative alternatives as the market reassesses tech and AI exposures.

Analysis

U.S. equities traded lower Monday as investors flagged stretched technology valuations and questioned the returns on heavy, debt-funded spending for AI and data centers; Amazon's reported $15 billion bond sale, its first in three years, is a notable liquidity event that benefits arranging banks Goldman Sachs, JPMorgan and Morgan Stanley. CNBC's Investing Club signaled a tactical rotation away from tech toward defensive areas, naming consumer packaged goods and healthcare as potential beneficiaries.

Kimberly-Clark was added to the Bullpen after announcing a roughly $49 billion enterprise-value acquisition of Kenvue that sent the stock down about 14% (from ~$120 to ~$102) and leaves K-C down roughly 20% year-to-date; management projects $2.4 billion of combined value from $1.9 billion in cost savings and ~$500 million of revenue synergies. The deal raises integration and headline-risk questions (Tylenol and U.K. talc litigation) but leaves Kimberly-Clark trading at under 14x 2026 EPS estimates with a 4.8% dividend yield, a modest valuation gap versus Procter & Gamble.

Johnson & Johnson, up ~38% YTD, was also added on durable oncology momentum (roughly $21 billion oncology sales in 2024, with a >$50 billion target by 2030) and the acquisition of Halda Therapeutics; management plans to shed a ~$9 billion orthopedics unit to redeploy capital into higher-growth franchises. J&J trades below 20x earnings, offering a defensive, cash-generative profile, but execution on the Halda buy and the spin-off will be key catalysts and risk points to monitor.

Key Decisions for Investors

• Consider a selective, size-limited buy of Kimberly-Clark to capture a sub-14x 2026 EPS valuation and 4.8% yield, but limit position size and set alerts for Kenvue integration updates and litigation headlines
• Consider adding or holding Johnson & Johnson on its oncology growth trajectory and recent asset buy (Halda), while monitoring pipeline readouts and progress on the orthopedics spin-off as execution-dependent catalysts
• Reduce or hedge high-beta tech/AI exposure in the near term given stretched valuations and uncertain ROI on debt-funded capex, and redeploy proceeds into defensive staples and healthcare names where fundamentals appear cheaper
• Take modest tactical exposure to investment banks (Goldman Sachs, JPMorgan, Morgan Stanley) that will benefit from large underwriting flows such as Amazon's $15 billion bond sale, while watching broader credit-market and fee-pressure dynamics